RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer
This study is to investigate the efficacy and safety of rhGM-CSF as adjuvant immunotherapy for patients with resectable stage III colon cancers.
Colon Cancer
DRUG: rhGM-CSF|DRUG: placebo
Disease-free survival（DFS）, 5 years
Immune anti-tumor effect: DC cells, CD4+ cells, CD8+ cells, Treg cells, 5|Overall survival (OS), 5 years|Incidence of liver metastasis, 5 years|Adverse effects (AE), 5 years
This study is to investigate the efficacy and safety of rhGM-CSF as adjuvant immunotherapy for patients with resectable stage III colon cancers. Patients were randomly assigned to rhGM-CSF group or placebo group and treated with rhGM-CSF or placebo perioperation and during the adjuvant chemotherapy. The purpose of the study is to evaluate the antitumor immune effect of rhGM-CSF before surgery and adjuvant chemotherapy through DFS of 5 years and to observe the safety during the treatment in order to provide evidence for improvement in treating resectable colon cancer patients.